AUA 2024 - American Urological Association Annual Meeting
May 03 - May 06, 2024 | San AntonioTXUS
LARVOL is not affiliated with American Urological Association Annual Meeting and all trademarks, logos, and brand names are property of their respective owners
Showing 182 abstracts linked to Trials
P2s: Paradigm-shifting, Practice-changing Clinical Trials in Urology: TAR-200 in patients with Bacillus Calmette–Guérin-unresponsive high-risk non–muscle-invasive bladder cancer: Results from SunRISe-1 study
PD34-11 - Nivolumab plus gemcitabine-cisplatin vs gemcitabine-cisplatin alone in patients with previously untreated unresectable/metastatic urothelial carcinoma: results of analyses to characterize benefit in responders from the phase 3 CheckMate 901 trial
Phase III, double-blind, placebo-controlled, 2-cohort, randomized study of saruparib (AZD5305) in combination with new hormonal agents in patients with metastatic castration-sensitive prostate cancer with and without homologous recombination repair mutati
PD01-06 - Prostate-specific antigen dynamics from the phase 3 EMBARK trial: A post hoc analysis
P2s: Paradigm-shifting, Practice-changing Clinical Trials in Urology: Pivotal Results from BOND-003: A Phase 3, Single-arm Study of Intravesical Cretostimogene Grenadenorepvec for the Treatment of High Risk, BCG-Unresponsive Non-Muscle Invasive Bladder C
P2s: Paradigm-shifting, Practice-changing Clinical Trials in Urology: The next generation trial: Assessing 18F-PSMA-1007 PET and MRI in primary staging of prostate cancer patients
P2-01 - TAR-200 IN PATIENTS WITH BACILLUS CALMETTE-GUERIN-UNRESPONSIVE HIGH-RISKNONeMUSCLE-INVASIVE BLADDER CANCER: RESULTS FROM SUNRISE-1 STUDY
P2s: Paradigm-shifting, Practice-changing Clinical Trials in Urology: SWOG S1011 – Subgroup analysis of the Phase III Surgical Trial to Evaluate the Benefit of a Standard Versus an Extended Lymphadenectomy Performed at Time of Radical Cystectomy for Muscl
P2s: Paradigm-shifting, Practice-changing Clinical Trials in Urology: Apalutamide and androgen deprivation therapy for the treatment of high-risk localized prostate cancer following radical prostatectomy in Apa-RP: a multicenter, open-label, single-arm ph
P2s: Paradigm-shifting, Practice-changing Clinical Trials in Urology: HIFI trial: HIFU vs Radical prostatectomy for localized Prostate cancer in 3328 cases. Final results.
PD42-11 - Development and validation of a multimodal artificial intelligence (MMAI)-derived digital pathology-based biomarker predicting metastasis for radical prostatectomy patients with biochemical recurrence in NRG/RTOG trials
PD38-02 - Avelumab first-line maintenance for advanced urothelial carcinoma: long-term outcomes from JAVELIN Bladder 100 in subgroups defined by first-line chemotherapy regimen and analysis of overall survival from start of first-line chemotherapy
PD01-03 - Third interim analysis (IA3) of the DARolutamide ObservationaL (DAROL) study in patients with nonmetastatic castration-resistant prostate cancer (nmCRPC)
MP16-09 - TRUCE04: A Phase II Clinical Trial of RC48 for High-Risk Non-Muscle-Invasive Bladder Cancer (HR-NMIBC) (NCT05495724)
MP01-12 - Accuracy of FDG-PET scan in primary testicular seminoma: Analysis from SEMS trial